Stempoint Capital LP bought a new stake in shares of Jade Biosciences, Inc. (NASDAQ:JBIO – Free Report) during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 154,034 shares of the company’s stock, valued at approximately $2,164,000. Stempoint Capital LP owned about 0.31% of Jade Biosciences as of its most recent filing with the SEC.
Other hedge funds also recently bought and sold shares of the company. Aberdeen Group plc purchased a new stake in shares of Jade Biosciences in the fourth quarter valued at $13,382,000. Baker BROS. Advisors LP purchased a new stake in Jade Biosciences during the 4th quarter worth about $25,323,000. Avidity Partners Management LP increased its position in Jade Biosciences by 24.3% during the 4th quarter. Avidity Partners Management LP now owns 1,400,708 shares of the company’s stock worth $21,613,000 after purchasing an additional 273,522 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new position in Jade Biosciences in the 1st quarter valued at about $353,000. Finally, 9823 Capital L.P. acquired a new position in Jade Biosciences in the 4th quarter valued at about $821,000.
Jade Biosciences Trading Down 1.8%
Jade Biosciences stock opened at $19.35 on Thursday. The stock has a fifty day moving average price of $19.82 and a 200 day moving average price of $18.20. Jade Biosciences, Inc. has a 52 week low of $6.67 and a 52 week high of $28.00. The firm has a market capitalization of $955.12 million, a P/E ratio of -9.58 and a beta of 1.43.
Wall Street Analyst Weigh In
Several equities research analysts have issued reports on JBIO shares. Weiss Ratings cut shares of Jade Biosciences from a “sell (d)” rating to a “sell (d-)” rating in a research note on Tuesday, June 16th. Guggenheim reissued a “buy” rating and issued a $47.00 price objective on shares of Jade Biosciences in a research report on Tuesday, June 2nd. Zacks Research raised shares of Jade Biosciences from a “strong sell” rating to a “hold” rating in a research note on Wednesday, April 8th. Wedbush upped their price objective on shares of Jade Biosciences from $34.00 to $45.00 and gave the company an “outperform” rating in a research note on Tuesday, June 2nd. Finally, Wall Street Zen lowered shares of Jade Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $51.57.
Check Out Our Latest Stock Report on Jade Biosciences
Jade Biosciences Profile
Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.
The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.
See Also
- Five stocks we like better than Jade Biosciences
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for Jade Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jade Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
